Skip to Content

Nkarta, Inc.

Company NameNkarta, Inc.
Stock SymbolNKTX

On March 21, 2024, Nkarta announced that it had “deprioritized” its acute myeloid leukemia program, NKX101, stating that the “response rate was meaningfully lower than that from the first 5 previously reported patients.”

On this news, Nkarta’s stock price fell $4.06, or 31.3%, to close at $8.92 per share on March 22, 2024, thereby injuring investors.

Submit Your Information

If you suffered a loss on your Nkarta, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

Shares Purchased

Number of SharesBuy DatePrice Per ShareAdd

Shares Sold

Number of SharesSell DatePrice Per ShareAdd